Medeon Biodesign (ROCO:6499) LT-Debt-to-Total-Asset : 0.06 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Medeon Biodesign's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.06.

Medeon Biodesign's long-term debt to total assets ratio increased from Mar. 2023 (0.05) to Jun. 2024 (0.06). It may suggest that Medeon Biodesign is progressively becoming more dependent on debt to grow their business.

Medeon Biodesign LT-Debt-to-Total-Asset Historical Data

The historical data trend for Medeon Biodesign's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign LT-Debt-to-Total-Asset Chart

Medeon Biodesign Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.14

0.04

Medeon Biodesign Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.05	0.05	0.06	0.06

Medeon Biodesign LT-Debt-to-Total-Asset Calculation

Medeon Biodesign's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	162.224	/	4040.023
	=	0.04

Medeon Biodesign's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	140.959	/	2299.417
	=	0.06

Medeon Biodesign (ROCO:6499) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Medeon Biodesign LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Medeon Biodesign Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170

Website

http://www.medeonbio.com

Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign Headlines

No Headlines